In 2022, the mortality rate of breast cancer in women in Europe was **** per 100,000 women. Cyprus had the highest mortality rate at **** per 100,000, followed by Slovakia with **** per 100,000 women. Conversely, Spain had the lowest mortality rate at **** per 100,000. This statistic depicts the mortality rate of breast cancer in Europe in 2022 in women population, by country.

In 2022, the highest cancer rate for men and women among European countries was in Denmark with 728.5 cancer cases per 100,000 population. Ireland and the Netherlands followed, with 641.6 and 641.4 people diagnosed with cancer per 100,000 population, respectively.
Lung cancer Lung cancer is the deadliest type of cancer worldwide, and in Europe, Germany was the country with the highest number of lung cancer deaths in 2022, with 47.7 thousand deaths. However, when looking at the incidence rate of lung cancer, Hungary had the highest for both males and females, with 138.4 and 72.3 cases per 100,000 population, respectively.
Breast cancer Breast cancer is the most common type of cancer among women with an incidence rate of 83.3 cases per 100,000 population in Europe in 2022. Cyprus was the country with the highest incidence of breast cancer, followed by Belgium and France. The mortality rate due to breast cancer was 34.8 deaths per 100,000 population across Europe, and Cyprus was again the country with the highest figure.

Dataset Description This dataset contains information on cancer deaths by country, type, and year. It includes data on 18 different types of cancer, including liver cancer, kidney cancer, larynx cancer, breast cancer, thyroid cancer, stomach cancer, bladder cancer, uterine cancer, ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer, esophageal cancer, testicular cancer, nasopharynx cancer, other pharynx cancer, colon and rectum cancer, non-melanoma skin cancer, lip and oral cavity cancer, brain and nervous system cancer, tracheal, bronchus, and lung cancer, gallbladder and biliary tract cancer, malignant skin melanoma, leukemia, Hodgkin lymphoma, multiple myeloma, and other cancers.

Data Fields The dataset includes the following data fields:

• Country: The country where the cancer death occurred.
• Code: The country code for the country where the cancer death occurred.
• Year: The year in which the cancer death occurred.
• Liver cancer: The number of cancer deaths from liver cancer in the country in the year.
• Kidney cancer: The number of cancer deaths from kidney cancer in the country in the year.
• Larynx cancer: The number of cancer deaths from larynx cancer in the country in the year.
• Breast cancer: The number of cancer deaths from breast cancer in the country in the year.
• Thyroid cancer: The number of cancer deaths from thyroid cancer in the country in the year.
• Stomach cancer: The number of cancer deaths from stomach cancer in the country in the year.
• Bladder cancer: The number of cancer deaths from bladder cancer in the country in the year.
• Uterine cancer: The number of cancer deaths from uterine cancer in the country in the year.
• Ovarian cancer: The number of cancer deaths from ovarian cancer in the country in the year.
• Cervical cancer: The number of cancer deaths from cervical cancer in the country in the year.
• Prostate cancer: The number of cancer deaths from prostate cancer in the country in the year.
• Pancreatic cancer: The number of cancer deaths from pancreatic cancer in the country in the year.
• Esophageal cancer: The number of cancer deaths from esophageal cancer in the country in the year.
• Testicular cancer: The number of cancer deaths from testicular cancer in the country in the year.
• Nasopharynx cancer: The number of cancer deaths from nasopharynx cancer in the country in the year.
• Other pharynx cancer: The number of cancer deaths from other pharynx cancer in the country in the year.
• Colon and rectum cancer: The number of cancer deaths from colon and rectum cancer in the country in the year.
• Non-melanoma skin cancer: The number of cancer deaths from non-melanoma skin cancer in the country in the year.
• Lip and oral cavity cancer: The number of cancer deaths from lip and oral cavity cancer in the country in the year.
• Brain and nervous system cancer: The number of cancer deaths from brain and nervous system cancer in the country in the year.
• Tracheal, bronchus, and lung cancer: The number of cancer deaths from tracheal, bronchus, and lung cancer in the country in the year.
• Gallbladder and biliary tract cancer: The number of cancer deaths from gallbladder and biliary tract cancer in the country in the year.
• Malignant skin melanoma: The number of cancer deaths from malignant skin melanoma in the country in the year.
• Leukemia: The number of cancer deaths from leukemia in the country in the year.
• Hodgkin lymphoma: The number of cancer deaths from Hodgkin lymphoma in the country in the year.
• Multiple myeloma: The number of cancer deaths from multiple myeloma in the country in the year.
• Other cancers: The number of cancer deaths from other cancers in the country in the year.

Data Source The data in this dataset was collected from the World Health Organization (WHO). The WHO collects data on cancer deaths from countries around the world.

Usage This dataset can be used to study cancer deaths by country, type, and year. It can also be used to compare cancer death rates between different countries or over time.

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16169071%2F98f6c6f321aad496b703685519b6df6a%2Fcancer-cells-th.jpg?generation=1694610742970317&alt=media" alt="">

BackgroundAmidst the rising breast cancer burden in Asia, we aim to predict the future mortality risk due to breast cancer and identify the risk-attributable deaths for breast cancer among East and South Asian countries.MethodsWe used country-level data to predict the trends in the next decade relating to female breast cancer mortality by employing data from 1990 to 2019 from the Global Burden of Disease 2019 study. We used the stochastic mortality modeling and prediction techniques to forecast the age-specific and risk-attributable breast cancer mortality trends at the regional and national levels of East and South Asia.ResultsThe number of deaths caused by the breast cancer is predicted to increase in East and South Asian countries in the next decade (2020–2030). Age-standardized death rate (ASDR) of breast cancer is predicted to increase by 7.0% from 9.20/100,000 (95% CI: 6.04–12.12) in 1990 to 9.88/100,000 (95% CI: 7.12–11.4) in 2030 in East Asia, and about 35% increase from 13.4/100,000 (95% CI: 9.21–16.02) in 1990 to 18.1/100,000 (95% CI: 13.23–21.10) in 2030 in South Asia. At the national level, the highest percent change in ASDR between 1990 and 2030 was reported in Pakistan (a 62% increase) and Nepal (a 47% increase). The highest percent change in breast cancer mortality between 2020 and 2030 for females of age group 80–84 years was observed in Pakistan [21.6, (95% CI, 20.6–94.7)], followed by Afghanistan [13.3 (4.0–80.8)], and Nepal [36.6 (11.1–125.7)] as compared to the other countries. In the females of aged 50–80 years, the predicted death rates were associated with high body mass index, high-fasting plasma glucose, and diet high in red meat, across the majority of countries under study. Furthermore, reductions in percent change in mortality rates occurred in several countries with increases in sociodemographic index (SDI), notably across high SDI countries.ConclusionBreast cancer mortality risk varies substantially across East and South Asian countries with higher mortality risk in low/middle SDI countries. Early detection using screening, awareness among females and health workers, and cost-effective and timely treatment of patients with breast cancer is vital in stemming the tide of breast cancer in the next decade.

The Latin American country with the highest age-standardized cancer mortality rate in 2022 was Uruguay, with ***** deaths per 100,000 population. Jamaica and Barbados followed, with cancer mortality rates of ***** and *****, respectively. As of that year, breast cancer was the cancer type with the highest incidence rate in Uruguay, as approximately ***** new cases were reported in the country.

Supplementary content:Table S1: GATHER statement checklist, with a description of compliance and location of information for "Breast Cancer Screening Programs and Breast Cancer Mortality: An Observational Study of 194 Countries”Table S2: Countries with regular breast cancer screening programs at the national level, 2015–2021Table S3: Countries with inconsistent breast cancer screening programs at the national level, 2015–21Table S4: Countries without any breast cancer screening programs at the national level, 2015–2021Table S5: Annualized changes in age-standardized breast cancer mortality across the countries from 2015–2021Table S6: European countries with mammographic screening coverage data, 2013–21Table S7: European countries with screening coverage data included or excluded from the analysisFig. S1. Annualized per cent changes in breast cancer deaths between countries with regular and irregular national breast cancer screening programmes, overall and by age group, 2015–2021 and 2015–2019 (analysis excluding the 21 outlier countries)Fig. S2. Annualized per cent changes in breast cancer deaths between countries with regular and irregular national breast cancer screening programmes, overall and by age group, 2015–2021 and 2015–2019 (among the 21 outlier countries)

BACKGROUND Comprehensive analyses of statistical data on breast cancer incidence, mortality, and associated risk factors are of great value for decision-making related to reducing the disease burden of breast cancer. METHODS: Based on data from the Annual Report of China Tumour Registry and the Global Burden of Disease (GBD), we conducted summary and trend analyses of incidence and mortality rates of breast cancer in Chinese women from 2014 to 2018 for urban and rural areas in the whole, eastern, central, and western parts of the country, and projected the incidence and mortality rates of breast cancer for 2019 in comparison with the GBD 2019 estimates. And the comparative risk assessment framework estimated risk factors contributing to breast cancer deaths and disability-adjusted life years (DALYs) from GBD. RESULTS: The Annual Report of the Chinese Tumour Registry showed that showed that the mortality rate of breast cancer declined and the incidence rate remained largely unchanged from 2014 to 2018. There was a significant increasing trend in incidence rates among urban and rural women in eastern China and rural women in central China, whereas there was a significant decreasing trend in mortality rates among rural women in China. The two data sources have some differences in their predictions of breast cancer in China in 2019. The GBD data estimated the age-standard DALYs rates of high body-mass index, high fasting plasma glucose and diet high in red meat, which are the top three risk factors attributable to breast cancer in Chinese women, to be 29.99/100,000, 13.66/100,000 and 13.44/100,000, respectively. Conclusion: The trend of breast cancer incidence and mortality rates shown in the Annual Report of China Tumour Registry indicates that China has achieved remarkable results in reducing the burden of breast cancer, but there is still a need to further improve breast cancer screening and early diagnosis and treatment, and to improve the system of primary prevention. The GBD database provides risk factors for breast cancer in the world, Asia, and China, and lays the foundation for research on effective measures to reduce the burden of breast cancer.

In 2010, cancer deaths accounted for more than 15% of all deaths worldwide, and this fraction is estimated to rise in the coming years. Increased cancer mortality has been observed in immigrant populations, but a comprehensive analysis by country of birth has not been conducted. We followed all individuals living in Sweden between 1961 and 2009 (7,109,327 men and 6,958,714 women), and calculated crude cancer mortality rates and age-standardized rates (ASRs) using the world population for standardization. We observed a downward trend in all-site ASRs over the past two decades in men regardless of country of birth but no such trend was found in women. All-site cancer mortality increased with decreasing levels of education regardless of sex and country of birth (p for trend <0.001). We also compared cancer mortality rates among foreign-born (13.9%) and Sweden-born (86.1%) individuals and determined the effect of education level and sex estimated by mortality rate ratios (MRRs) using multivariable Poisson regression. All-site cancer mortality was slightly higher among foreign-born than Sweden-born men (MRR = 1.05, 95% confidence interval 1.04–1.07), but similar mortality risks was found among foreign-born and Sweden-born women. Men born in Angola, Laos, and Cambodia had the highest cancer mortality risk. Women born in all countries except Iceland, Denmark, and Mexico had a similar or smaller risk than women born in Sweden. Cancer-specific mortality analysis showed an increased risk for cervical and lung cancer in both sexes but a decreased risk for colon, breast, and prostate cancer mortality among foreign-born compared with Sweden-born individuals. Further studies are required to fully understand the causes of the observed inequalities in mortality across levels of education and countries of birth.

In 2018, Croatia reported **** cancer deaths from colorectal cancer per 100,000 population, the highest mortality rate of colorectal cancer in Europe. In the same year, Croatia reported also to have the highest mortality rate of breast cancer (females only) with **** deaths per 100,000 population, while Estonia reported to have the highest mortality rate of prostate cancer with **** deaths per 100,000 population. This statistic shows the mortality rates of selected types of cancers in European countries in 2018.

Breast cancer is a worldwide threat to female health with patient outcomes varying widely. The exact correlation between global outcomes of breast cancer and the national socioeconomic status is still undetermined. Mortality-to-incidence ratio (MIR) of breast cancer was calculated with the contemporary age standardized incidence and mortality rates for countries with data available at GLOBOCAN 2012 database. The MIR matched national human development indexes (HDIs) and health system attainments were respectively obtained from Human Development Report and World Health Report. Correlation analysis, regression analysis, and Tukey-Kramer post hoc test were used to explore the effects of HDI and health system attainment on breast cancer MIR. Our results demonstrated that breast cancer MIR was inversely correlated with national HDI (r = -.950; P < .001) and health system attainment (r = -.898; P < .001). Countries with very high HDI had significantly lower MIRs than those with high, medium and low HDI (P < .001). Liner regression model by ordinary least squares also indicated negative effects of both HDI (adjusted R2 = .903, standardize β = -.699, P < .001) and health system attainment (adjusted R2 =. 805, standardized β = -.009; P < .001), with greater effects in developing countries identified by quantile regression analysis. It is noteworthy that significant health care disparities exist among countries in accordance with the discrepancy of HDI. Policies should be made in less developed countries, which are more likely to obtain worse outcomes in female breast cancer, that in order to improve their comprehensive economic strength and optimize their health system performance.

📄 Dataset Description: This dataset contains global cancer patient data reported from 2015 to 2024, designed to simulate the key factors influencing cancer diagnosis, treatment, and survival. It includes a variety of features that are commonly studied in the medical field, such as age, gender, cancer type, environmental factors, and lifestyle behaviors. The dataset is perfect for:

Exploratory Data Analysis (EDA)

Multiple Linear Regression and other modeling tasks

Feature Selection and Correlation Analysis

Predictive Modeling for cancer severity, treatment cost, and survival prediction

Data Visualization and creating insightful graphs

Key Features: Age: Patient's age (20-90 years)

Gender: Male, Female, or Other

Country/Region: Country or region of the patient

Cancer Type: Various types of cancer (e.g., Breast, Lung, Colon)

Cancer Stage: Stage 0 to Stage IV

Risk Factors: Includes genetic risk, air pollution, alcohol use, smoking, obesity, etc.

Treatment Cost: Estimated cost of cancer treatment (in USD)

Survival Years: Years survived since diagnosis

Severity Score: A composite score representing cancer severity

This dataset provides a broad view of global cancer trends, making it an ideal resource for those learning data science, machine learning, and statistical analysis in healthcare.

This data package contains mortality and morbidity estimates for adult, maternal, and child mortalities as well as mortalities from diseases like malaria and breast and cervical cancer.

PurposesMost molecular-based published studies on breast cancer do not adequately represent the unique and diverse genetic admixture of the Latin American population. Searching for similarities and differences in molecular pathways associated with these tumors and evaluating its impact on prognosis may help to select better therapeutic approaches.Patients and MethodsWe collected clinical, pathological, and transcriptomic data of a multi-country Latin American cohort of 1,071 stage II-III breast cancer patients of the Molecular Profile of Breast Cancer Study (MPBCS) cohort. The 5-year prognostic ability of intrinsic (transcriptomic-based) PAM50 and immunohistochemical classifications, both at the cancer-specific (OSC) and disease-free survival (DFS) stages, was compared. Pathway analyses (GSEA, GSVA and MetaCore) were performed to explore differences among intrinsic subtypes.ResultsPAM50 classification of the MPBCS cohort defined 42·6% of tumors as LumA, 21·3% as LumB, 13·3% as HER2E and 16·6% as Basal. Both OSC and DFS for LumA tumors were significantly better than for other subtypes, while Basal tumors had the worst prognosis. While the prognostic power of traditional subtypes calculated with hormone receptors (HR), HER2 and Ki67 determinations showed an acceptable performance, PAM50-derived risk of recurrence best discriminated low, intermediate and high-risk groups. Transcriptomic pathway analysis showed high proliferation (i.e. cell cycle control and DNA damage repair) associated with LumB, HER2E and Basal tumors, and a strong dependency on the estrogen pathway for LumA. Terms related to both innate and adaptive immune responses were seen predominantly upregulated in Basal tumors, and, to a lesser extent, in HER2E, with respect to LumA and B tumors.ConclusionsThis is the first study that assesses molecular features at the transcriptomic level in a multicountry Latin American breast cancer patient cohort. Hormone-related and proliferation pathways that predominate in PAM50 and other breast cancer molecular classifications are also the main tumor-driving mechanisms in this cohort and have prognostic power. The immune-related features seen in the most aggressive subtypes may pave the way for therapeutic approaches not yet disseminated in Latin America.Clinical Trial RegistrationClinicalTrials.gov (Identifier: NCT02326857).

Breast Cancer Diagnostic Market Outlook

The global breast cancer diagnostic market size was valued at approximately USD 4.5 billion in 2023 and is projected to reach USD 9.2 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.5% during the forecast period. The rising prevalence of breast cancer, coupled with advances in diagnostic technologies, significantly drives the market growth. Other factors include increased awareness about early detection and the availability of substantial government funding for cancer research and diagnostics.

One of the primary growth factors in the breast cancer diagnostic market is the increasing incidence of breast cancer globally. According to the World Health Organization (WHO), breast cancer is the most common cancer among women worldwide, leading to significant morbidity and mortality. The rising awareness about the importance of early diagnosis, which significantly improves survival rates, has encouraged more women to undergo regular screenings. This has, in turn, driven the demand for advanced diagnostic tools and technologies.

Technological advancements in diagnostic tools are another critical growth driver for the breast cancer diagnostic market. Innovations such as digital mammography, 3D imaging, and artificial intelligence (AI)-driven diagnostic solutions have revolutionized the early detection and accurate diagnosis of breast cancer. These technologies offer enhanced image clarity, reduced false positives, and faster results, leading to better patient outcomes. Continuous research and development in this area are expected to bring more sophisticated and effective diagnostic solutions to the market.

The increasing availability of government and private funding for breast cancer research and diagnostic initiatives also propels market growth. Many countries have implemented screening programs and awareness campaigns to educate women about the importance of early detection. Additionally, several non-profit organizations and advocacy groups are actively involved in promoting breast cancer awareness and funding research projects, further boosting the demand for diagnostic services.

From a regional perspective, North America dominates the breast cancer diagnostic market, followed by Europe, due to the high prevalence of breast cancer, well-established healthcare infrastructure, and significant investment in research and development. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by increasing awareness, improving healthcare facilities, and rising healthcare expenditure in countries such as China and India.

Test Type Analysis

The breast cancer diagnostic market can be segmented by test type into mammography, biopsy, ultrasound, MRI, CT scan, PET scan, and others. Mammography is the most commonly used test for breast cancer screening and diagnosis. Digital mammography, which offers superior image quality and lower radiation exposure compared to traditional film mammography, has gained significant traction. The advent of 3D mammography or tomosynthesis has further enhanced the accuracy of breast cancer detection, reducing false positives and improving patient outcomes.

Biopsy remains the gold standard for definitive diagnosis of breast cancer. Various biopsy techniques such as fine-needle aspiration, core needle biopsy, and surgical biopsy are employed based on the clinical scenario. The integration of imaging technologies with biopsy procedures, such as stereotactic and ultrasound-guided biopsies, has improved the precision and accuracy of tissue sampling, thereby enhancing diagnostic outcomes. The development of minimally invasive biopsy techniques has also reduced patient discomfort and recovery time.

Ultrasound is commonly used as an adjunct to mammography to evaluate breast abnormalities, particularly in women with dense breast tissue. The non-invasive nature of ultrasound, combined with its ability to differentiate between cystic and solid masses, makes it a valuable tool in breast cancer diagnosis. Advances in ultrasound technology, such as the development of elastography, have further improved its diagnostic accuracy by assessing tissue stiffness, which is indicative of malignancy.

MRI and PET scans are primarily used for staging breast cancer and evaluating the extent of disease spread. MRI offers excellent soft tissue contrast and is particularly useful in assessing the involvement of the chest wall and lymph nodes. PET scans, on the other hand, provide functional

BackgroundA rapid surge of female breast cancer has been observed in young women in several East Asian countries. The BIM deletion polymorphism, which confers cell resistance to apoptosis, was recently found exclusively in East Asian people with prevalence rate of 12%. We aimed to evaluate the possible role of this genetic alteration in carcinogenesis of breast cancer in East Asians.MethodFemale healthy volunteers (n = 307), patients in one consecutive stage I-III breast cancer cohort (n = 692) and one metastatic breast cancer cohort (n = 189) were evaluated. BIM wild-type and deletion alleles were separately genotyped in genomic DNAs.ResultsBoth cancer cohorts consistently showed inverse associations between the BIM deletion polymorphism and patient age (≤35 y vs. 36-50 y vs. >50 y: 29% vs. 22% vs. 15%, P = 0.006 in the consecutive cohort, and 40% vs. 23% vs. 13%, P = 0.023 in the metastatic cohort). In healthy volunteers, the frequencies of the BIM deletion polymorphism were similar (13%-14%) in all age groups. Further analyses indicated that the BIM deletion polymorphism was not associated with specific clinicopathologic features, but it was associated with poor overall survival (adjusted hazard ratio 1.71) in the consecutive cohort.ConclusionsBIM deletion polymorphism may be involved in the tumorigenesis of the early-onset breast cancer among East Asians.

Breast Cancer Therapeutics Market Outlook

As per our latest research, the global breast cancer therapeutics market size reached USD 27.8 billion in 2024, reflecting robust growth driven by technological advancements and increasing disease prevalence worldwide. The market is poised to expand at a CAGR of 8.6% during the forecast period, with projections indicating the market will attain a value of USD 57.3 billion by 2033. This remarkable growth trajectory is underpinned by rising awareness regarding early diagnosis, expanding access to advanced therapies, and continuous innovation in targeted treatments. The breast cancer therapeutics market is experiencing a transformative phase, with significant investments in research and development, fostering the introduction of novel drugs and personalized medicine approaches.

One of the primary growth factors for the breast cancer therapeutics market is the increasing incidence and prevalence of breast cancer globally. According to the World Health Organization, breast cancer remains the most common cancer among women, accounting for nearly 2.3 million new cases annually. The rising burden of this disease, coupled with the aging population and lifestyle-related risk factors, has heightened the demand for effective therapeutic interventions. Furthermore, the growing emphasis on routine screening and early detection initiatives has led to a surge in diagnosed cases, necessitating timely and advanced treatment options. The integration of artificial intelligence and digital health solutions in diagnostics and treatment planning is also contributing to improved patient outcomes and driving market expansion.

Another significant driver is the rapid advancement in drug development, particularly in targeted therapy and immunotherapy. Pharmaceutical companies are increasingly focusing on the development and commercialization of monoclonal antibodies, hormone therapies, and novel immunotherapeutics that offer superior efficacy and safety profiles compared to conventional chemotherapy. The approval of innovative drugs such as CDK4/6 inhibitors, PARP inhibitors, and immune checkpoint inhibitors has revolutionized the treatment landscape, enabling personalized and precision medicine approaches. These advancements are not only enhancing survival rates but also improving the quality of life for breast cancer patients. Additionally, supportive government initiatives, favorable reimbursement policies, and expanding clinical trial activities are further catalyzing market growth.

The expanding availability and accessibility of breast cancer therapeutics in emerging markets are also contributing to market growth. Countries in Asia Pacific and Latin America are witnessing increased healthcare investments, improved infrastructure, and rising awareness about cancer prevention and treatment. This has led to greater adoption of advanced therapies and a shift towards patient-centric care models. Moreover, collaborations between global pharmaceutical companies and local healthcare providers are facilitating the introduction of novel therapeutics in these regions. The growing penetration of online pharmacies and telemedicine platforms is also enhancing access to breast cancer drugs, especially in remote and underserved areas.

From a regional perspective, North America continues to dominate the breast cancer therapeutics market, accounting for the largest share in 2024, driven by high healthcare expenditure, advanced research capabilities, and a well-established regulatory framework. Europe follows closely, with significant contributions from countries like Germany, France, and the United Kingdom. The Asia Pacific region is anticipated to exhibit the fastest growth during the forecast period, owing to rising cancer incidence, increasing healthcare investments, and expanding patient access to innovative therapies. Latin America and the Middle East & Africa are also expected to witness steady growth, supported by improving healthcare infrastructure and growing awareness about breast cancer management.

Therapy Type Analysis

The breast cancer therapeutics market is segmented by therapy type into chemotherapy, hormone therapy, targeted therapy, immunotherapy, and others. Chemotherapy remains a cornerstone of breast cancer treatment, particularly for advanced and metastatic cases. Despite the emergence of newer therapies, chemotherapy continues to be widely used due to its proven efficacy in reducing tumor burden and preventing disease recurrence. However, the ma

Goal of the Competition The goal of this competition is to identify breast cancer. You'll train your model with screening mammograms obtained from regular screening.

Your work improving the automation of detection in screening mammography may enable radiologists to be more accurate and efficient, improving the quality and safety of patient care. It could also help reduce costs and unnecessary medical procedures.

Context According to the WHO, breast cancer is the most common cancer worldwide. In 2020 alone, there were 2.3 million new breast cancer diagnoses and 685,000 deaths. Yet breast cancer mortality in high-income countries had dropped by 40% since the 1980s when health authorities implemented regular mammography screening in at-risk age groups. Early detection and treatment are critical to reducing cancer fatalities, and your machine-learning skills could help streamline the process radiologists use to evaluate screening mammograms.

Currently, early detection of breast cancer requires the expertise of highly-trained human observers, making screening mammography programs expensive to conduct. A looming shortage of radiologists in several countries will likely worsen this problem. Mammography screening also leads to a high incidence of false positive results. This can result in unnecessary anxiety, inconvenient follow-up care, extra imaging tests, and sometimes a need for tissue sampling (often a needle biopsy).

The competition host, the Radiological Society of North America (RSNA) is a non-profit organization that represents 31 radiologic subspecialties from 145 countries around the world. RSNA promotes excellence in patient care and health care delivery through education, research, and technological innovation.

Your efforts in this competition could help extend the benefits of early detection to a broader population. Greater access could further reduce breast cancer mortality worldwide.

We have data for patients with breast implants.

The file contains separate sheets that provide pertinent metadata for assessing the incidence and mortality rates of breast cancer based on various factors such as time, gender, region, country, and socio-demographic index (SDI). In addition to this information, the document also includes data on the World population age standard, the HDI of different countries in 1990, and Global Population Forecasts spanning from 2017 to 2100.

Background: Breast cancer in young women is quite uncommon and shows more aggressive characteristics with major disparities between worldwide populations. Prognosis and outcome of breast cancer in young patients are widely studied, but still no consensus is available. Methods: We retrospectively included 716 cases of breast cancer women diagnosed in 2009 at the National Institute of Oncology of Rabat. Patients were divided into two groups according to their age: women aged ≤40 years (Group 1) and women aged >40 years (Group 2). Data were recorded from patients' medical files and analyzed using SPSS 13.0 software (IBM). Results: Young patients represent 24.9% of all patients with breast cancer. The comparison between the two groups displayed significant differences regarding nulliparity (p = 0.001) and progesterone receptor negativity (p = 0.01). Moreover, more progression (Metastases/Relapse) was registered in young women as compared to older women with breast cancer (p = 0.03). The estimated median follow-up period was 31 months. The 5-years Event-Free Survival (EFS) of patients with local disease was 64.6% in young women and 71.5% in older women with breast cancer (p = 0.04). Multivariate analysis in young women showed that nulliparity (HR: 7.2; 95%CI: 1.16–44.54; p = 0.03), T3 tumors (HR: 17.39; 95%CI: 1.74–173.34; p = 0.01) and negative PgR status (HR: 19.85; 95%CI: 1.07–366.54; p = 0.04) can be considered as risk factors for poorer event free survival while hormone therapy was associated with better EFS (HR: 0.11; 95%CI: 0.00–0.75; p = 0.03). In Group 2, multivariate analysis showed that patients with inflammatory breast cancer, N+ status, absence of radiotherapy, absence of chemotherapy, and absence of hormone therapy are at increased risk of recurrence. Conclusions: In Morocco, breast cancer is more frequent in young women as compared to western countries. Breast cancer in young women is more aggressive and is diagnosed late, leading to an intensive treatment. Moreover, the main factors associated with breast cancer development in young women would be hormonal and reproductive status. Analysis of other genetic biomarkers is needed to explain the high prevalence of breast cancer in young women to improve breast cancer management in Morocco

BackgroundThe nationwide HUN-CANCER EPI study examined cancer incidence and mortality rates in Hungary from 2011 to 2019.MethodsUsing data from the National Health Insurance Fund (NHIF) and Hungarian Central Statistical Office (HCSO), our retrospective study analyzed newly diagnosed malignancies between Jan 1, 2011, and Dec 31, 2019. Age-standardized incidence and mortality rates were calculated for all and for different tumor types using both the 1976 and 2013 European Standard Populations (ESP).FindingsThe number of newly diagnosed cancer cases decreased from 60,554 to 56,675 between 2011–2019. Age-standardized incidence rates were much lower in 2018, than previously estimated (475.5 vs. 580.5/100,000 person-years [PYs] in males and 383.6 vs. 438.5/100,000 PYs in females; ESP 1976). All-site cancer incidence showed a mean annual decrease of 1.9% (95% CI: 2.4%-1.4%) in men and 1.0% (95% CI:1.42%-0.66%) in women, parallel to mortality trends (-1.6% in males and -0.6% in females; ESP 2013). In 2018, the highest age-standardized incidence rates were found for lung (88.3), colorectal (82.2), and prostate cancer (62.3) in men, and breast (104.6), lung (47.7), and colorectal cancer (45.8) in women. The most significant decreases in incidence rates were observed for stomach (4.7%), laryngeal (4.4%), and gallbladder cancers (3.5%), with parallel decreases in mortality rates (3.9%, 2.7% and 3.2%, respectively).InterpretationWe found a lower incidence of newly diagnosed cancer cases for Hungary compared to previous estimates, and decreasing trends in cancer incidence and mortality, in line with global findings and the declining prevalence of smoking.